ArticleSurgical case reports2026
Exceptional Long-Term Survival after Resection of Metachronous Liver and Lung Metastases Following Surgery for Pancreatic Cancer: A Case Report.
Article in Surgical case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPancreatic ductal adenocarcinoma (PDAC) has a poor prognosis, especially in patients with distant metastases. However, recent advances in multidisciplinary treatment strategies, including surgical resection, have led to successful outcomes even in patients with metastatic PDAC. Nevertheless, few cases have been reported with 2 or more resections of metachronous distant metastases. Herein, we report a case of PDAC in which a metachronous hepatic metastasis was successfully resected following prolonged chemotherapy after curative pancreatectomy and in which a metachronous pulmonary metastasis was subsequently resected following additional chemotherapy. CASE PRESENTATION: A 69-year-old man was diagnosed with PDAC and received neoadjuvant chemotherapy in October 2019. In March 2020, a subtotal stomach-preserving pancreaticoduodenectomy was performed. The patient received 1 year of adjuvant chemotherapy following surgery. In September 2021, 18 months after surgery, CT showed a 10-mm nodule in segment (S) 6 of the liver, which was diagnosed as a hepatic recurrence of PDAC. After 19 months of chemotherapy, the metastatic liver lesion remained solitary and showed no change in size, suggesting that the tumor was well-controlled. In June 2023, a partial hepatectomy of S6 was performed. Chemotherapy with S-1 was continued after hepatic resection; however, a metastatic pulmonary lesion in the right lower lobe was identified on CT 15 months after the liver surgery. Right lower lobe partial resection was performed using video-assisted thoracoscopic surgery in January 2025. The patient remains alive and recurrence-free 1 year after the last surgery, 6 years and 1 month after the initial surgery, and 6 years and 6 months after the start of treatment.
conclusionsThis report describes a case of long-term survival achieved with a multidisciplinary approach, including 2 surgical resections, for recurrent disease following a diagnosis of PDAC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.